Corcept Therapeutics (CORT) Investor presentation summary

Operating model and strategy

• Q1–Q3 2026 revenue rose from $165M to $341M; Q3 mix was $249M Korlym and $91M Lifyorli. Cash was $662M at Q3-end; FY2026 revenue guidance is $1.1B–$1.2B.

• Strategy combines a cash-generating operating model, a broad cortisol-modulation therapeutic platform and collaborative R&D.

• Korlym, Lifyorli and next-generation selective cortisol modulators compete with cortisol at the glucocorticoid receptor; none bind the progesterone receptor.

Hypercortisolism and Cushing’s syndrome

• Relacorilant’s pivotal Phase 3 GRACE trial met its primary endpoint; patients continuing treatment were 5.9x more likely to maintain blood-pressure response than placebo recipients.

• In GRACE’s open-label phase, patients with hypertension had mean reductions of 12.6 mm Hg in SBP and 8.3 mm Hg in DBP; patients with hyperglycemia had a mean 0.7% HbA1c improvement.

• GRADIENT showed placebo-adjusted improvements in blood pressure, glucose measures, weight and body composition; weight improvement was 3.9 kg at 22 weeks (p=0.0001).

• Relacorilant’s resubmitted NDA has a PDUFA date of December 17, 2026; composition-of-matter patents extend to 2038, with method, formulation and manufacturing patents to 2040.

• CATALYST found hypercortisolism in 24% of screened patients with resistant T2D; Korlym reduced HbA1c by 1.47% versus 0.15% with placebo over 24 weeks (p<0.001).

Oncology

• Lifyorli (relacorilant) plus nab-paclitaxel was FDA-approved in March 2026 for specified platinum-resistant ovarian, fallopian tube or primary peritoneal cancer; it became a preferred NCCN regimen in April 2026.

• In ROSELLA, the combination improved median PFS to 6.5 vs. 5.5 months (HR 0.70; p=0.0076) and median OS to 16.0 vs. 11.9 months (HR 0.65; p=0.0004) versus nab-paclitaxel alone.

• BELLA Part A reported 7.2-month median PFS and 59% ORR overall; bevacizumab-naive patients had 8.1-month median PFS and 66% ORR.

• BELLA Parts B and C, TRIDENT and STELLA are Phase 2 chemotherapy-combination studies in ovarian, endometrial, pancreatic and cervical cancers; several results are expected by year-end 2027.

• Phase 2 relacorilant plus enzalutamide prostate cancer and Phase 1b nenocorilant plus nivolumab solid-tumor studies are enrolling; results are expected by year-end 2027.